FarmaKology-New deep screening technique enables rapid discovery of high-affinity antibodies to clinically relevant drug targets
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "abdul@farmakology.com", and happy to have you featured on our newsletter+20K Subs.
Today's Company
Sosei Heptares
Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions. Our global business combines our world-leading GPCR-targeted StaR® technology, structure-based drug design and early development capabilities in the UK with a highly experienced clinical development capability and a commercial operation in Japan. We are leveraging these capabilities to generate and advance a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases. We intend to develop these opportunities for patients in Japan and globally both internally and through our partnerships with global biopharmaceutical companies and emerging technology companies. Sosei Heptares operates from key locations in Tokyo and Osaka (Japan), London and Cambridge (UK) and Seoul (South Korea).
News
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of acute myeloid leukemia (AML).
Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma
Cellipont Bioservices, a leading CDMO in cell therapy development and manufacturing and Diakonos Oncology, announced today that they have entered into an agreement for the Process Development & cGMP Manufacturing of DOC1021, an autologous dendritic cell vaccine being manufactured for the treatment of glioblastoma multiforme (GBM) and other cancer indications.
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has awarded the company a contract to support the development of oral ceftibuten-ledaborbactam etzadroxil for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring cell therapies to patients on a global scale. The USD 250 million investment will support the production of material required for clinical trials and potential commercial launch of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson’s Disease.
Research & Study
Xenon’s Add-On Epilepsy Treatment Shows Promising Phase IIb Efficacy, Safety
New deep screening technique enables rapid discovery of high-affinity antibodies to clinically relevant drug targets
Podcast
Job Opportunities
Medical Representative
Pharmacy Technician
clinical pharmacist
Pharmacist
Savings up to 40% on Top Hearing Aid Brands
Get Web Hosting + Domain Name for fixed yearly price.
Create amazing content quickly with Canva – no design skills needed
Upcoming Webinar & Event
Covalent Drug Discovery: Basic Principles and Analysis of Current Patent Literature
Representativeness: A Failing Flaw in Traditional Clinical Trial Design
Video
